181 related articles for article (PubMed ID: 8102552)
1. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
Goff DC; Renshaw PF; Sarid-Segal O; Dreyfuss DA; Amico ET; Ciraulo DA
Biol Psychiatry; 1993 May; 33(10):700-6. PubMed ID: 8102552
[TBL] [Abstract][Full Text] [Related]
2. Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study.
Kojima T; Yamauchi T; Miyasaka M; Koshino Y; Nakane Y; Takahashi R; Shimazono Y; Yagi G
Psychiatry Res; 1992 Aug; 43(2):129-36. PubMed ID: 1357701
[TBL] [Abstract][Full Text] [Related]
3. Nifedipine in the treatment of tardive dyskinesia.
Duncan E; Adler L; Angrist B; Rotrosen J
J Clin Psychopharmacol; 1990 Dec; 10(6):414-6. PubMed ID: 1981070
[TBL] [Abstract][Full Text] [Related]
4. Treatment of tardive dyskinesia with donepezil: a pilot study.
Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
[TBL] [Abstract][Full Text] [Related]
5. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
6. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
Andrew HG
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO
Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
[TBL] [Abstract][Full Text] [Related]
8. Buspirone in the treatment of tardive dyskinesia.
Moss LE; Neppe VM; Drevets WC
J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
[TBL] [Abstract][Full Text] [Related]
9. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
10. Association of negative symptoms with tardive dyskinesia in schizophrenic patients.
Chiu H; Lau J; Lam L; Shum P
Aust N Z J Psychiatry; 1993 Jun; 27(2):228-32. PubMed ID: 8103320
[TBL] [Abstract][Full Text] [Related]
11. Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures.
Yuen O; Caligiuri MP; Williams R; Dickson RA
Br J Psychiatry; 1996 Jun; 168(6):702-8. PubMed ID: 8773812
[TBL] [Abstract][Full Text] [Related]
12. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
13. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
[TBL] [Abstract][Full Text] [Related]
14. Akathisia: clinical phenomenology and relationship to tardive dyskinesia.
Kahn EM; Munetz MR; Davies MA; Schulz SC
Compr Psychiatry; 1992; 33(4):233-6. PubMed ID: 1353716
[TBL] [Abstract][Full Text] [Related]
15. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Pappa S; Tsouli S; Apostolou G; Mavreas V; Konitsiotis S
Clin Neuropharmacol; 2010; 33(6):271-5. PubMed ID: 21121175
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
[TBL] [Abstract][Full Text] [Related]
17. Fluperlapine in tardive dyskinesia and parkinsonism.
Korsgaard S; Noring U; Gerlach J
Psychopharmacology (Berl); 1984; 84(1):76-9. PubMed ID: 6149595
[TBL] [Abstract][Full Text] [Related]
18. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects.
McCreadie RG; MacDonald E; Wiles D; Campbell G; Paterson JR
Br J Psychiatry; 1995 Nov; 167(5):610-7. PubMed ID: 8564316
[TBL] [Abstract][Full Text] [Related]
19. Tardive dyskinesia--diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service.
Lauterbach EC; Carter WG; Rathke KM; Thomas BH; Shillcutt SD; Vogel RL; Moore NC; Mimbs JW; Nelson WH
Schizophr Bull; 2001; 27(4):601-13. PubMed ID: 11824487
[TBL] [Abstract][Full Text] [Related]
20. Tardive dyskinesia and positive symptoms of schizophrenia.
White T; Brown KW; Woods JP
Acta Psychiatr Scand; 1991 May; 83(5):377-9. PubMed ID: 1677232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
